These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 29523800)

  • 21. Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-β pathology.
    Suárez-Calvet M; Morenas-Rodríguez E; Kleinberger G; Schlepckow K; Araque Caballero MÁ; Franzmeier N; Capell A; Fellerer K; Nuscher B; Eren E; Levin J; Deming Y; Piccio L; Karch CM; Cruchaga C; Shaw LM; Trojanowski JQ; Weiner M; Ewers M; Haass C;
    Mol Neurodegener; 2019 Jan; 14(1):1. PubMed ID: 30630532
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tau or neurofilament light-Which is the more suitable biomarker for Huntington's disease?
    Niemelä V; Landtblom AM; Blennow K; Sundblom J
    PLoS One; 2017; 12(2):e0172762. PubMed ID: 28241046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alterations in the tyrosine and phenylalanine pathways revealed by biochemical profiling in cerebrospinal fluid of Huntington's disease subjects.
    Herman S; Niemelä V; Emami Khoonsari P; Sundblom J; Burman J; Landtblom AM; Spjuth O; Nyholm D; Kultima K
    Sci Rep; 2019 Mar; 9(1):4129. PubMed ID: 30858393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease.
    De Vos A; Jacobs D; Struyfs H; Fransen E; Andersson K; Portelius E; Andreasson U; De Surgeloose D; Hernalsteen D; Sleegers K; Robberecht C; Van Broeckhoven C; Zetterberg H; Blennow K; Engelborghs S; Vanmechelen E
    Alzheimers Dement; 2015 Dec; 11(12):1461-1469. PubMed ID: 26092348
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cerebrospinal Fluid Biomarkers for Huntington's Disease.
    Byrne LM; Wild EJ
    J Huntingtons Dis; 2016; 5(1):1-13. PubMed ID: 27031730
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke.
    De Vos A; Bjerke M; Brouns R; De Roeck N; Jacobs D; Van den Abbeele L; Guldolf K; Zetterberg H; Blennow K; Engelborghs S; Vanmechelen E
    BMC Neurol; 2017 Aug; 17(1):170. PubMed ID: 28854881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1-42)/Aβ(1-40).
    Vanderstichele H; Demeyer L; Janelidze S; Coart E; Stoops E; Mauroo K; Herbst V; François C; Hansson O
    Alzheimers Res Ther; 2017 Jun; 9(1):40. PubMed ID: 28587660
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuropeptide Y (NPY) in cerebrospinal fluid from patients with Huntington's Disease: increased NPY levels and differential degradation of the NPY1-30 fragment.
    Wagner L; Björkqvist M; Lundh SH; Wolf R; Börgel A; Schlenzig D; Ludwig HH; Rahfeld JU; Leavitt B; Demuth HU; Petersén Å; von Hörsten S
    J Neurochem; 2016 Jun; 137(5):820-37. PubMed ID: 27016395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cerebrospinal fluid neurogranin in an inducible mouse model of neurodegeneration: A translatable marker of synaptic degeneration.
    Höglund K; Schussler N; Kvartsberg H; Smailovic U; Brinkmalm G; Liman V; Becker B; Zetterberg H; Cedazo-Minguez A; Janelidze S; Lefevre IA; Eyquem S; Hansson O; Blennow K
    Neurobiol Dis; 2020 Feb; 134():104645. PubMed ID: 31669672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CSF neurogranin as a neuronal damage marker in CJD: a comparative study with AD.
    Blennow K; Diaz-Lucena D; Zetterberg H; Villar-Pique A; Karch A; Vidal E; Hermann P; Schmitz M; Ferrer Abizanda I; Zerr I; Llorens F
    J Neurol Neurosurg Psychiatry; 2019 Aug; 90(8):846-853. PubMed ID: 31097472
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status.
    Piccio L; Deming Y; Del-Águila JL; Ghezzi L; Holtzman DM; Fagan AM; Fenoglio C; Galimberti D; Borroni B; Cruchaga C
    Acta Neuropathol; 2016 Jun; 131(6):925-33. PubMed ID: 26754641
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease.
    Kvartsberg H; Duits FH; Ingelsson M; Andreasen N; Öhrfelt A; Andersson K; Brinkmalm G; Lannfelt L; Minthon L; Hansson O; Andreasson U; Teunissen CE; Scheltens P; Van der Flier WM; Zetterberg H; Portelius E; Blennow K
    Alzheimers Dement; 2015 Oct; 11(10):1180-90. PubMed ID: 25533203
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology.
    Portelius E; Olsson B; Höglund K; Cullen NC; Kvartsberg H; Andreasson U; Zetterberg H; Sandelius Å; Shaw LM; Lee VMY; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk DA; McCluskey L; Elman L; McBride J; Toledo JB; Trojanowski JQ; Blennow K
    Acta Neuropathol; 2018 Sep; 136(3):363-376. PubMed ID: 29700597
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease.
    Kester MI; Teunissen CE; Crimmins DL; Herries EM; Ladenson JH; Scheltens P; van der Flier WM; Morris JC; Holtzman DM; Fagan AM
    JAMA Neurol; 2015 Nov; 72(11):1275-80. PubMed ID: 26366630
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synaptic Molecular and Neurophysiological Markers Are Independent Predictors of Progression in Alzheimer's Disease.
    Smailovic U; Kåreholt I; Koenig T; Ashton NJ; Winblad B; Höglund K; Nilsson P; Zetterberg H; Blennow K; Jelic V
    J Alzheimers Dis; 2021; 83(1):355-366. PubMed ID: 34334389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cerebrospinal Fluid YKL-40 and Neurogranin in Familial Alzheimer's Disease: A Pilot Study.
    Thordardottir S; Almkvist O; Johansson C; Zetterberg H; Blennow K; Graff C
    J Alzheimers Dis; 2020; 76(3):941-953. PubMed ID: 32568193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of Cerebrospinal Fluid Soluble TREM2 and Polymorphisms in Sporadic Parkinson's Disease in a Chinese Population.
    Peng G; Qiu J; Liu H; Zhou M; Huang S; Guo W; Lin Y; Chen X; Li Z; Li G; Zhang W; Zhang Y; Li X; Wu Z; Wei L; Yang X; Zhu X; Mo M; Xu P
    J Mol Neurosci; 2020 Feb; 70(2):294-301. PubMed ID: 31833018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ubiquitin: a potential cerebrospinal fluid progression marker in Huntington's disease.
    Vinther-Jensen T; Simonsen AH; Budtz-Jørgensen E; Hjermind LE; Nielsen JE
    Eur J Neurol; 2015 Oct; 22(10):1378-84. PubMed ID: 26073975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup.
    Woollacott IOC; Nicholas JM; Heslegrave A; Heller C; Foiani MS; Dick KM; Russell LL; Paterson RW; Keshavan A; Fox NC; Warren JD; Schott JM; Zetterberg H; Rohrer JD
    Alzheimers Res Ther; 2018 Aug; 10(1):79. PubMed ID: 30111356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cerebrospinal fluid glial fibrillary acidic protein, in contrast to amyloid beta protein, is associated with disease symptoms in Huntington's disease.
    Korpela S; Sundblom J; Zetterberg H; Constantinescu R; Svenningsson P; Paucar M; Niemelä V
    J Neurol Sci; 2024 Apr; 459():122979. PubMed ID: 38569376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.